Question 1

What is Ottimo Healthcare Fund I's investment strategy?

Accepted Answer

Ottimo Healthcare Fund I is a £100m clinician-led Private Equity fund executing a buy-and-build consolidation strategy in the UK lower-mid-market healthcare sector. We acquire sub-scale independent clinics, diagnostic chains, and specialist hubs at attractive entry multiples, integrate them into our proprietary tech-enabled operating playbook (Medroid AI + Rainbow Diagnostics), and drive rapid 30%+ EBITDA expansion. The goal is to build a £30m+ EBITDA national platform positioned for a premium exit to Large-Cap PE or strategic acquirers in Year 5–7.

Question 2

What types of healthcare assets does the Fund acquire?

Accepted Answer

The Fund targets sub-scale independent clinics, diagnostic chains, and specialist hubs in the UK lower-mid-market with enterprise values of £20m–£50m. Specific target profiles include: (1) Retiring founder-owned regional hospital groups (1-3 sites); (2) Sub-scale Community Diagnostic Centres (CDCs); (3) Occupational Health networks; (4) Independent diagnostic and imaging centers. We focus primarily on London, South East, and Home Counties, acquiring assets at 6x–7x EV/EBITDA entry multiples with conservative 40-50% senior debt leverage.

Question 3

What is the Fund's structure and key terms?

Accepted Answer

Ottimo Healthcare Fund I is structured as a Closed-Ended Limited Partnership with a 10-year term, domiciled in Guernsey as a PIF. Key terms: Target Size £100m (Hard Cap £120m); Management Fee 2.0% on Committed Capital (100% offset against operating fees charged to portfolio companies); Carried Interest 20% over an 8% Preferred Return (European Waterfall / Whole-Fund); GP Commitment 1.5% (£1.5m via Big-4 validated CHC equity rollover); Investment/Harvest Period: 5-year investment period, 5-year harvest period.

Question 4

What is the typical acquisition process and timeline?

Accepted Answer

Our acquisition process follows these stages: (1) Initial screening and preliminary analysis (1-2 weeks); (2) Management meetings and site visits (2-3 weeks); (3) Due diligence including clinical, financial, and regulatory review led by Big Four advisors (4-8 weeks); (4) Valuation and deal structuring with conservative 40-50% senior debt leverage (2-3 weeks); (5) Legal documentation via Tier-1 law firms and completion (4-6 weeks). The entire process typically takes 3-5 months from initial contact to completion. During the 5-year investment period, we target 4-6 platform acquisitions with bolt-on add-ons.

Question 5

What is the Chelmsford Health Centre seed asset?

Accepted Answer

Chelmsford Health Centre (CHC) is the Fund's proprietary seed asset, bypassing the traditional 'blind pool' setup phase. CHC is a fully operational, CQC-regulated multi-specialty hub in Essex offering urgent care, GP services, cardiology, paediatrics, and advanced diagnostics. With 5,000+ registered patients, a 4.9-star rating, and 95% of patients seen within 20 minutes, CHC provides de-risked Day 1 deployment. The GP is rolling 100% of their 65% equity stake in CHC into the Fund to satisfy the £1.5m GP Commitment. CHC serves as the operational 'Hub' for future 'Spoke' clinic acquisitions, with complex diagnostics and specialty referrals routed back to CHC to drive utilization and profitability.

Question 6

What is the Fund's operational alpha and value creation strategy?

Accepted Answer

Acquired clinics are immediately integrated into our proprietary tech-enabled operating playbook: (1) Medroid AI: Automated clinical triage, digital patient acquisition, and workflow optimization that strips £100ks in legacy administrative overhead; (2) Rainbow Diagnostics: Rapid, ISO-accredited in-house pathology that replaces slow, high-margin outsourced lab contracts. These platforms are external vendors contracted at strictly benchmarked, arm's-length market rates. Critically, any operating, advisory, or board fees charged by the GP to portfolio companies are deducted pound-for-pound from the LP Management Fee (100% offset), ensuring exceptional LP alignment. This operational alpha drives rapid 30%+ EBITDA expansion, transforming single-digit margin clinics into 20%+ EBITDA assets.

Question 7

How can I invest in Ottimo Healthcare Fund I as an LP?

Accepted Answer

Ottimo Healthcare Fund I is currently raising capital toward its £100m target size (Hard Cap £120m). We welcome inquiries from institutional investors, family offices, and qualified high-net-worth individuals who understand the UK healthcare market and PE fund structures. The Fund offers a compelling risk-adjusted return profile with de-risked Day 1 deployment via the CHC seed asset. Interested LPs should contact invest@ottimoholdings.com with information about their investment criteria, ticket size, and relevant healthcare or PE experience. Our team will provide the full LP pitch deck, fund terms, and due diligence materials.

Question 8

How can I sell my healthcare business to the Fund?

Accepted Answer

If you own a UK healthcare business in the £20m–£50m enterprise value range (retiring founder-owned regional hospital groups, diagnostic chains, specialist clinics, or occupational health networks), we'd be interested in learning more. Please visit our Deal Analyzer tool at ottimoholdings.com/deal-analyzer to submit your business information and financial data. Our AI-powered system will provide an initial assessment, and our team will follow up within 48 hours for qualifying opportunities. Alternatively, you can contact deals@ottimoholdings.com directly. We move quickly, maintain strict confidentiality, and work with Tier-1 advisors to ensure a smooth transaction.

Frequently Asked Questions